|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Merck KGaA-Deals & Alliances Report
|
Mar 2011 |
£380 |
100% |
Merck KGaA
Strategy, SWOT, and Corporate Finance Report
|
Jun 2011 |
£79 |
99% |
Merck KGaA – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
94% |
Prospects for Pharma Mergers, Acquisitions and Alliances
2010-2020
|
Jul 2010 |
£1,499 |
87% |
Partnering Yearbook
2012
|
Jan 2012 |
£1,895 |
82% |
Partnering Agreements with Bigpharma
3rd Edition
|
Oct 2010 |
£630 |
81% |
|
Pharmaceutical Partnership Deal Terminations
|
Sep 2011 |
£2,215 |
81% |
Mergers and Aquisitions in the Pharmaceuticals Sector, 2009
Critical success factors for competing in a consolidating market
|
Apr 2009 |
£995 |
81% |
Partnering and M&A Yearbook
2012
|
Jan 2012 |
£2,210 |
81% |
Esophageal Cancer Therapeutics
Pipeline Assessment and Market Forecast to 2017
|
Jul 2011 |
£1,265 |
78% |
Systemic Lupus Erythematosus Therapeutics (SLE)
Pipeline Assessment and Market Forecasts to 2018
|
Oct 2011 |
£2,215 |
77% |
Bristol-Myers Squibb Company - Pharmaceuticals & Healthcare
Deals and Alliances Profile
|
Jul 2009 |
£160 |
75% |
|
Biomarker Partnering Terms and Agreements
|
Feb 2012 |
£1,705 |
72% |
|
Melanoma Therapeutics
|
Apr 2010 |
£2,500 |
72% |
Allergic Rhino-Conjunctivitis - Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
70% |
Cancer Therapies
Global Market Opportunities
|
Nov 2009 |
£1,895 |
70% |
Germany Pharmaceuticals and Healthcare Report Q2
2011
|
Feb 2011 |
£330 |
70% |
Infertility - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
69% |
|
M&A trends in Pharma
|
Oct 2008 |
£7,210 |
68% |
Pipeline Insight: Therapeutic Cancer Vaccines
Prospect of first approval set to reinvigorate interest from major companies
|
Dec 2009 |
£7,210 |
68% |
Consolidation in the Generic Pharmaceutical Industry
An Evolving Landscape
|
Oct 2007 |
£1,250 |
68% |
|
Mylan Inc.: PharmaVitae Profile
|
Jan 2010 |
£3,605 |
68% |
Osteoarthritis - Pipeline Review
Q1 2011
|
Feb 2011 |
£315 |
68% |
Serono
PharmaVitae Profile
|
Oct 2006 |
£3,600 |
67% |
Astrocytoma - Pipeline Review
H2 2011
|
Aug 2011 |
£315 |
67% |
M&A Yearbook
2012
|
Jan 2012 |
£1,895 |
66% |
Squamous Cell Carcinoma - Pipeline Review
H2 2011
|
Aug 2011 |
£315 |
66% |
Obesity - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
66% |
|
Pharmaceutical Regulatory Affairs in The Eu & US
|
Jan 2006 |
£1,095 |
65% |
Multiple Myeloma (Kahler's Disease) - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
65% |
